Publications

2010

Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, et al. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010;85(9):664-9.
Magro CM, Cruz-Inigo AE, Votava H, Jacobs M, Wolfe D, A Crowson N. Drug-associated reversible granulomatous T cell dyscrasia: a distinct subset of the interstitial granulomatous drug reaction. J Cutan Pathol. 2010;37 Suppl 1:96-111.
Zadra G, Priolo C, Patnaik A, Loda M. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res. 2010;16(13):3322-8.
Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, et al. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion. 2010;50(2):471-7.
Magro CM, A Crowson N, Mihm MC, Kline M. De novo intraepidermal epithelioid melanocytic dysplasia: an emerging entity. J Cutan Pathol. 2010;37(8):866-9.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899-905.
Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, et al. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer. 2010;103(7):1025-33.
Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer. 2010;102(10):1495-502.
Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, et al. Tissue-based molecular markers for bladder cancer. Minerva Urol Nefrol. 2010;62(3):241-58.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700